Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
News
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL…
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL…
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase…
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage…
VantAI Announces Formation of Scientific Advisory Board
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — VantAI, a leading company focused on the…
VantAI Announces Formation of Scientific Advisory Board
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — VantAI, a leading company focused on the…
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage…
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…